<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827943</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-08</org_study_id>
    <nct_id>NCT01827943</nct_id>
  </id_info>
  <brief_title>Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer</brief_title>
  <acronym>VESTOR</acronym>
  <official_title>Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the absence of standard treatment in this indication, this test evaluates a new drug type
      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the absence of standard treatment in this indication, this test evaluates a new drug type
      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and
      survival. This study will also search for genes involved in the response to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the efficacy of Temsirolimus (Torisel ®) in terms of non-progression rate (PR+CR+SD) after 2 months of treatment</measure>
    <time_frame>12/2013 (2 months)</time_frame>
    <description>Evaluation of the efficacy of Temsirolimus (Torisel ®) in terms of non-progression rate (PR+CR+SD) after 2 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Progression free survival • Duration of response • Time to progression • Overall survival • Quality of life</measure>
    <time_frame>12/2013 (2 months)</time_frame>
    <description>Progression free survival
Duration of response
Time to progression
Overall survival
Quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Relapsed Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>TORISEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torisel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TORISEL</intervention_name>
    <description>Temsirolimus</description>
    <arm_group_label>TORISEL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of at least 18 years of age

          -  Histologically proven Bladder cancer

          -  Locally advanced or metastatic disease (stage IV)

          -  Functional status (ECOG / OMS) ≤ 2

          -  Relapse after first-line chemotherapy

          -  Measurable lesions (RECIST criteria)

          -  Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.

          -  Biological levels :

          -  Neutrophil count &gt;1,5.109/L.

          -  Platelets &gt;100.109/L

          -  Total serum bilirubin &lt; 1.5 × ULN

          -  Clearance of créatinine 40 ml/mm

          -  If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) &lt;2.5 × ULN

          -  With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;5 ×
             ULN

          -  Signed informed consent

          -  Both women and men must agree to use a medically acceptable method of contraception
             throughout the study. Women of childbearing potential must have a negative serum
             pregnancy test of or less than 7 days before the first perfusion of study.

          -  France only : Patients affiliated to a social security program

        Exclusion Criteria:

          -  Presence of metastatic brain or meningeal tumors on selection scanner, weither
             symptomatic or asymptomatic

          -  Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion

          -  Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or
             polysorbate 80 or to their excipients

          -  Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma
             curatively treated) or incidental (≤ pT2) prostate cancer found on a radical
             cystoprostatectomy material

          -  The drugs known as CYP3A4/5 inhibitors or inducers will specifically be excluded on
             the 30th day ( or at least 7 halves-lives, according to the shortest duration) before
             the first perfusion and throughout the study. Any food known to inhibit CYP3A4/5 (for
             example grapefruit, grapefruit juice, star-fruit or star-fruit juice) will also be
             purposely excluded.

          -  Auto-immune pathology, psychiatric or neurological disorder

          -  Any unstable medical condition

          -  Unstable cardiac disease

          -  Severe renal failure

          -  Unstable diabetes

          -  Pregnancy

          -  Patient enrolled in another therapeutic clinical trial

          -  Patient unable to follow and comply with the study procedures because of any
             geographical, social or medical condition

          -  Patient partially or totally deprived of his civil rights
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine HOUEDE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des armées du Val-de-Grâce</name>
      <address>
        <city>Paris</city>
        <zip>75230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.e-cancer.fr/les-essais-cliniques/registre-des-essais-cliniques</url>
    <description>Institut National du Cancer</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

